Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × enfortumab vedotin × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 9 Urinary Bladder Neoplasms 3 Urethral Neoplasms 1 Ureteral Neoplasms 1 Peripheral Nervous System Diseases 1 Neoplasm Metastasis 1 Muscle-invasive Bladder Cancer 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Metastatic Urothelial Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Bladder Cancer 1

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡